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INTRODUCTION
Trigger Finger Release Performed Wide Awake: Prospective 
Comparsion of Local Anesthetics 
Constantinos Ketonis, MD, PhD(n); Nayoung Kim, BS (n); Frederic Liss, MD (2,5-Pacira); Benjamin Zmistowski, MD (n); Jonas L. Matzon, MD (n); 
Charles Leinberry, MD (1,2,3B, 4- Knee Creations; 3C- SegWay Orthopedics; 1,2,4-Zimmer); Mark Wang, MD (n); Christopher Jones, MD (n); William Kirkpatrick, MD (n); Asif Ilyas, MD (7-Jaypee Medical Publishers)
Investigation performed at the Rothman Institute at Thomas Jeerson University, Phladelphia, PA.
MATERIALS AND METHODS
DISCUSSION
Trigger nger (TF) is one of the most common conditions treated by hand surgeons with a 
lifetime risk up to 10% in patients with diabetes. If conservative management fails, surgical 
treatment is undertaken, with or without sedation and a tourniquet, via a small incision to 
release the A1 pulley. A number of local anesthetics are readily available including Lidocaine, 
Ropivacaine and Marcaine as well as encapsulated formulations thereof such as Exparel. 
Since it’s approval in 2011, there have been numerous reports of successfully achieving pro-
longed pain relief with locally injected Exparel after various procedures, but to the best of 
our knowledge there have been no reports of its use in ambulatory hand surgery. In this 
study we prospectively evaluated the ecacy of Lidocaine, Marcaine, or bupivacaine with 
post-operative Exparel in controlling pain, opioid usage, and adverse reactions following TF 
surgery.
After obtaining institutional review board (IRB) approval, all consecutive patients scheduled 
to undergo single digit TF surgery were invited to participate. All procedures were performed 
under local anesthesia without sedation by one of seven fellowship-trained hand surgeons. 
The technique for injection was that of a single volar injection at the level of the A1 pulley 
with a volume of 5-10 ml of local anesthetic delivered subcutaneously and supercial to the 
exor tendon sheath. The injectate consisted of either a) 1% Lidocaine, b) 0.5% Marcaine, or 
0.5% bupivacaine with post-operative injection of 5cc of Exparel into the closed surgical site. 
Patients were instructed to record their medication use, their pain levels using a Visual 
Analog Scale (VAS) scoring system and any adverse reactions experienced. An analysis of 
variance was used to detect signicant dierences between groups. To the best of our knowledge this is the rst report on the comparative ecacy of local anes-
thetics in ambulatory hand surgery specically comparing Lidocaine, Marcaine, and Exparel. 
Our results suggest that patients treated with Marcaine attain better pain control than those 
treated with Lidocaine on POD 0-1, but only patients that receive Exparel maintain the lowest 
pain levels through POD 0-3. More importantly, this is achieved while using little-to-no opioid 
medications and with less adverse reactions than with Lidocaine or Marcaine alone. In agree-
ment with what has been reported in other series, Exparel generally appears to make most of 
the dierence in pain perception in the rst 1-2 days after surgery. Overall, pain following trig-
ger nger release surgery performed wide-awake and without a tourniquet is low. However, 
longer pain relief, decreased opioid consumption, and a better adverse reaction prole is a 
goal that physicians and patients strive to achieve. More studies are needed to validate both 
the ecacy and cost of Exparel versus other local anesthetic agents in patients undergoing 
more extensive and painful hand and orthopaedic surgical procedures.
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DEMOGRAPHICS
Patients were enrolled over a 6 month period in 2014. The study consisted of a total of 163 
patients (85 women and 78 men), with only 9 patients lost to follow up for an overall attrition 
rate of 5.5%. After excluding patients lost to follow up, the Marcaine group included 50 pa-
tients with average age of 61.3, the Lidocaine group included 53 patients with average age of 
65, and the Exparel group included 51 patients with average age of 64.
RESULTS
DISCUSSION
OPIOID CONSUMPTION: PERCENT OF PATIENT USAGE
On POD 0, 58% (p=0.01) and 59% (p=0.004) of 
patients that received Marcaine and Lidocaine,
respectively, used opioids for pain control as 
compared to 27% of patients in the Exparel 
group. 
By POD 1, Exparel patients maintained the 
lowest opioid consumption at 33.3%, where 44% 
(p=0.271) and 45% (p=0.213) of the Lidocaine 
and Marcaine patients used opioids. 
At POD 2 the percentage of patients using opi-
oids continued to decrease in all groups and 
converged to about 15% by POD 3.
VISUAL ANALOG SCALE (VAS) SCORES 
Patients were contacted on POD 3 and asked 
about their pain levels over POD 0-3. On POD 0 
patients in the Lidocaine group reported the 
most pain. On POD 1 this dierence was main-
tained with the lidocaine group at 3.73 as com-
pared to the Marcaine and Exparel groups at 2.90 
(p=0.116) and 2.33 (p=0.003), respectively.Only 
the Exparel group maintained signicance on 
POD 1. In contrast, on POD 2 and POD 3 the dif-
ferences were more subtle and did not reach sta-
tistical signicance.
OPIOID CONSUMPTION: NUMBER OF TABLETS
A similar trend is seen when the average total 
number of opioid pills consumed by these groups is 
analyzed. The only  statistically dierent pill con-
sumption was observed on POD 0  where opioid 
users in the lidocaine group  consumed an average of 
1.62 pills as compared to  1.08 (p=0.214) and 0.70 
(p=0.013) pills in the Marcaine and Exparel group, 
respectively. Total pill consumption on POD 1-3 was 
similar in all  groups.
PAIN-FREE PATIENTS WITHOUT OPIOIDS
An analysis of patients that were deemed pain-free 
(VAS score ≤2) while also not using any opioid medi-
cation revealed that on POD 0, 50% of patients that 
received Exparel were pain-free without requiring 
opioids, which was statistically higher than Lidocaine 
at 16% (p=0.002) and Marcaine at 21% (p=0.017). This 
trend continued on POD 1 with Exparel at 47% 
(p=0.474), Marcaine at 40% and Lidocaine at 32% 
(p=0.118). By POD 2-3 the patients in this category 
converged with no statistical dierences.
ADVERSE EFFECTS
The percentage of patients reporting any adverse reac-
tions at any time in the rst 3 days after surgery was sig-
nicantly lower in the Exparel group (3%) as compared 
to the Marcaine 13% ( p = 0.017) and Lidocaine 10% 
(p=0.133) group. The most common reactions reported 
included dry mouth, nausea, lack of energy and itching 
whereas the least common reactions were dizziness, 
coughing and a sensation of bloating.
